Cardanol-derived AChE inhibitors: Towards the development of dual binding derivatives for Alzheimer's disease

. 2016 Jan 27 ; 108 () : 687-700. [epub] 20151217

Jazyk angličtina Země Francie Médium print-electronic

Typ dokumentu časopisecké články, Research Support, N.I.H., Extramural, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/pmid26735910
Odkazy

PubMed 26735910
DOI 10.1016/j.ejmech.2015.12.024
PII: S0223-5234(15)30412-8
Knihovny.cz E-zdroje

Cardanol is a phenolic lipid component of cashew nut shell liquid (CNSL), obtained as the byproduct of cashew nut food processing. Being a waste product, it has attracted much attention as a precursor for the production of high-value chemicals, including drugs. On the basis of these findings and in connection with our previous studies on cardanol derivatives as acetylcholinesterase (AChE) inhibitors, we designed a novel series of analogues by including a protonable amino moiety belonging to different systems. Properly addressed docking studies suggested that the proposed structural modifications would allow the new molecules to interact with both the catalytic active site (CAS) and the peripheral anionic site (PAS) of AChE, thus being able to act as dual binding inhibitors. To disclose whether the new molecules showed the desired profile, they were first tested for their cholinesterase inhibitory activity towards EeAChE and eqBuChE. Compound 26, bearing an N-ethyl-N-(2-methoxybenzyl)amine moiety, showed the highest inhibitory activity against EeAChE, with a promising IC50 of 6.6 μM, and a similar inhibition profile of the human isoform (IC50 = 5.7 μM). As another positive feature, most of the derivatives did not show appreciable toxicity against HT-29 cells, up to a concentration of 100 μM, which indicates drug-conform behavior. Also, compound 26 is capable of crossing the blood-brain barrier (BBB), as predicted by a PAMPA-BBB assay. Collectively, the data suggest that the approach to obtain potential anti-Alzheimer drugs from CNSL is worth of further pursuit and development.

Citace poskytuje Crossref.org

Nejnovějších 20 citací...

Zobrazit více v
Medvik | PubMed

Synthesis and In Vitro Evaluation of Novel Dopamine Receptor D2 3,4-dihydroquinolin-2(1H)-one Derivatives Related to Aripiprazole

. 2021 Aug 24 ; 11 (9) : . [epub] 20210824

Discovery of sustainable drugs for Alzheimer's disease: cardanol-derived cholinesterase inhibitors with antioxidant and anti-amyloid properties

. 2021 Jul 21 ; 12 (7) : 1154-1163. [epub] 20210505

Sustainable Drug Discovery of Multi-Target-Directed Ligands for Alzheimer's Disease

. 2021 Apr 22 ; 64 (8) : 4972-4990. [epub] 20210408

Novel Sustainable-by-Design HDAC Inhibitors for the Treatment of Alzheimer's Disease

. 2019 Apr 11 ; 10 (4) : 671-676. [epub] 20190329

Derivatives of the β-Crinane Amaryllidaceae Alkaloid Haemanthamine as Multi-Target Directed Ligands for Alzheimer's Disease

. 2019 Apr 03 ; 24 (7) : . [epub] 20190403

Profiling donepezil template into multipotent hybrids with antioxidant properties

. 2018 Dec ; 33 (1) : 583-606.

Development of 2-Methoxyhuprine as Novel Lead for Alzheimer's Disease Therapy

. 2017 Jul 28 ; 22 (8) : . [epub] 20170728

Novel Tacrine-Scutellarin Hybrids as Multipotent Anti-Alzheimer's Agents: Design, Synthesis and Biological Evaluation

. 2017 Jun 16 ; 22 (6) : . [epub] 20170616

Synthesis and Biological Evaluation of Benzochromenopyrimidinones as Cholinesterase Inhibitors and Potent Antioxidant, Non-Hepatotoxic Agents for Alzheimer's Disease

. 2016 May 14 ; 21 (5) : . [epub] 20160514

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...